Last reviewed · How we verify
UPA-EC
UPA-EC, developed by Columbia University, is a marketed drug that interacts with a specific target in the body to produce a desired effect. The key composition patent for UPA-EC is set to expire in 2028, which may provide a period of market exclusivity and competitive advantage. However, the lack of specified primary indication and revenue data poses a significant risk in assessing its market potential and financial impact.
At a glance
| Generic name | UPA-EC |
|---|---|
| Also known as | Ulipristal acetate (UPA) emergency contraceptive (EC), ella |
| Sponsor | Columbia University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg (PHASE4)
- Effectiveness of Orally Dosed Emergency Contraception in Obese Women - UPA (PHASE4)
- EC PK in Women With Normal and Obese BMI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UPA-EC CI brief — competitive landscape report
- UPA-EC updates RSS · CI watch RSS
- Columbia University portfolio CI